HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 14 (6) , 1919-1929
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (26870390)
This publication has 39 references indexed in Scilit:
- Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)Molecular and Clinical Oncology, 2013
- Target Points in Trastuzumab ResistanceInternational Journal of Breast Cancer, 2012
- EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer CellsPLOS ONE, 2011
- Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF NanomedicineClinical Cancer Research, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted miceBiomaterials, 2009
- Efficient Gene Delivery Vectors by Tuning the Surface Charge Density of Amino Acid-Functionalized Gold NanoparticlesACS Nano, 2008
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997